-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3

Benzinga·03/12/2026 16:34:32
Listen to the news
Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $4 to $3.